Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma?

Steven Chun-Min Shih, Harjot Singh Vohra, Sahar Khan, Salman Basrai, Esther Masih-Khan, Anup Devasia, Donna Reece, Suzanne Trudel, Keith Stewart, Sita Bhella, Vishal Kukreti, Chloe Yang, Guido Lancman, Rodger Tiedemann, Anca Prica, Eugene Leung, Aaron Schimmer, Sagi Abelson, Christine Chen

Blood (2025) 146 (Supplement 1): 5773.

https://doi.org/10.1182/blood-2025-5773

Published: 2025

Journal Articles

The mitochondrial protease YME1L regulates type 1 interferon signaling via the cgas-sting pathway in AML

Yihe Zhang, Geethu Thomas, Rose Hurren, Yongran Yan, Dakai Ling, Marcela Gronda, Andrea Arruda, Mark Minden, Aaron Schimmer

Blood (2025) 146 (Supplement 1): 6765.

https://doi.org/10.1182/blood-2025-6765

Published: 2025

Journal Articles

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Akhil Rajendra, Dawn Maze, Aniket Bankar, Steven Chan, Marta Davidson, Vikas Gupta, Mark Minden, Maria Perusini, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Elliot Smith, Karen W.L. Yee, Hassan Sibai

Blood (2025) 146 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2025-1672

Published: 2025

Journal Articles

Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study.

Zahra AlHaj Issa, Cristiano Machado De Freitas, Aarya Murali, Akhil Rajendra, Dawn Maze, Aniket Banker, Steven Chan, Marta Davidson, Aaron Schimmer, Andre Schuh, Hassan Sibai, Karen W.L. Yee, Mark Minden, Vikas Gupta, Maria Perusini, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 3390.

https://doi.org/10.1182/blood-2025-3390

Published: 2025

Journal Articles

Extramedullary disease in AML: A high-risk feature beyond ELN 2022 classification

Yael Morgenstern, Claire Andrews, Eshetu Atenafu, Steven Chan, Vikas Gupta, Mark Minden, Dawn Maze, Aaron Schimmer, Andre Schuh, Karen W.L. Yee, Hassan Sibai

Blood (2025) 146 (Supplement 1): 3388.

https://doi.org/10.1182/blood-2025-3388

Published: 2025

Journal Articles

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

Aarya Murali, Zahra AlHaj Issa, Cristiano Machado De Freitas, Akhil Rajendra, Marta Davidson, Aniket Bankar, Hassan Sibai, Maria Perusini, Steven Chan, Aaron Schimmer, Mark Minden, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Dawn Maze, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 3508.

https://doi.org/10.1182/blood-2025-3508

Published: 2025

Journal Articles

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Josephine Anne Lucero, Maria Perusini, Aniket Bankar, Marta Davidson, Guillaume Richard-Carpentier, Aaron Schimmer, Andre Schuh, Dawn Maze, Karen W.L. Yee, Mark Minden, Steven Chan, Jose-Mario Capo-Chichi, Vikas Gupta, Hassan Sibai, Anne Tierens, Dennis Kim

Blood (2025) 146 (Supplement 1): 7051.

https://doi.org/10.1182/blood-2025-7051

Published: 2025

Journal Articles

Ribosome biogenesis and its regulation by the exportin, CSE1L, are targetable vulnerabilities in childhood and young adult Acute Myeloid Leukemia

Grace Egan, Amit Kumar, Veronique Voisin, Rose Hurren, Ali Chegini, Dakai Ling, Geethu Thomas, Yongran Yan, Yue Feng, Nathan Duong, Dilshad Khan, Chaitra Sarathy, Suraj Bansal, Andy Zeng, Fieke Hoff, Steven Kornblau, John Dick, Johann Hitzler, Aaron Schimmer

Blood (2025) 146 (Supplement 1): 1452.

https://doi.org/10.1182/blood-2025-1452

Published: 2025

Journal Articles

Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics

Elizabeth Herrity, Dawn Maze, Marta Davidson, Aniket Bankar, Maria Perusini, Hassan Sibai, Steven Chan, Aaron Schimmer, Mark Minden, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 5240.

https://doi.org/10.1182/blood-2025-5240

Published: 2025

Journal Articles

Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes

Ana Patiño, Hong Chang, Mark Turingan, Aniket Bankar, Jonathan Wei, Marta Davidson, Guillaume Richard-Carpentier, Mark Minden, Andre Schuh, Karen W.L. Yee, Vikas Gupta, Dawn Maze, Steven Chan, Aaron Schimmer, Claire Andrews, Hassan Sibai, Maria Perusini

Blood (2025) 146 (Supplement 1): 3330.

https://doi.org/10.1182/blood-2025-3330

Published: 2025

Journal Articles

Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study

Cristiano Machado De Freitas, Aarya Murali, Zahra AlHaj Issa, Aniket Bankar, Hassan Sibai, Maria Perusini, Aaron Schimmer, Mark Minden, Steven Chan, Karen W.L. Yee, Andre Schuh, Vikas Gupta, Dawn Maze, Marta Davidson, Guillaume Richard-Carpentier

Blood (2025) 146 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2025-4776

Published: 2025

Journal Articles

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Blood (2024) 144 (Supplement 1): 1506.

https://doi.org/10.1182/blood-2024-204004

Published: 2024

Journal Articles

Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study

Sahar Khan, Salman Basrai, Esther Masih-Khan, Harjot Vohra, Donna Reece, Suzanne Trudel, Keith Stewart, Sita D. Bhella, Vishal Kukreti, Chloe Yang, Rodger E Tiedemann, Anca Prica, Aaron Schimmer, Sagi Abelson, Christine I Chen

Blood (2024) 144 (Supplement 1): 1954.

https://doi.org/10.1182/blood-2024-210717

Published: 2024

Journal Articles

Mitochondrial Dysfunction in Normal and Malignant Hematopoiesis

Aaron Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): SCI-11.

https://doi.org/10.1182/blood-2018-99-109470

Published: 2018

Journal Articles

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Supercomplex Formation and Represents a New Therapeutic Target for AML

Sara Mirali, Botham Aaron, Veronique Voisin, PhD, Yihua Qiu, Fieke W Hoff, BSc, Rose Hurren, BSc, Marcela Gronda, MSc, Yulia Jitkova, PhD, G. Wei Xu, Neil MacLean, Xiaoming Wang, Terzah M. Horton, MD PhD, Steven M. Kornblau, MD, Steven M Chan, MD PhD, Gary D Bader, Aaron Schimmer, MD PhD

Blood (2018) 132 (Supplement 1): 1335.

https://doi.org/10.1182/blood-2018-99-110869

Published: 2018

Journal Articles

Targeting the Mitochondrial Metallochaperone Cox17 Reduces DNA Methylation and Promotes AML Differentiation through a Copper Dependent Mechanism

Blood (2018) 132 (Supplement 1): 1339.

https://doi.org/10.1182/blood-2018-99-111015

Published: 2018

Journal Articles

Tafazzin (TAZ) Regulates the Differentiation of AML Cells By Reducing Levels of the Phospholipid Phosphatidylethanolamine

Blood (2017) 130 (Supplement 1): 788.

https://doi.org/10.1182/blood.V130.Suppl_1.788.788

Published: 2017

Journal Articles

The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules

Dina Khalaf, MD BSc, Steven M. Chan, MD PhD, Vikas Gupta, MD PhD, Andrzej Lutynski, MD, Dawn Maze, MD FRCPC, MSc, Mark D. Minden, MD PhD, Yoichiro Natori, MD, Rhea Pavan, BA, Amr Rostom, MD, Anna Rydlewski, MD, Aaron Schimmer, MD PhD, Andre Schuh, MD FRCPC, Hassan Sibai, MBBS, Karen W.L. Yee, MD, Shahid Husain, MD MS

Blood (2017) 130 (Supplement 1): 4682.

https://doi.org/10.1182/blood.V130.Suppl_1.4682.4682

Published: 2017

Journal Articles

Migration in the Management of Philadelphia Positive ALL: Towards a Lower Risk of VTE

Hassan Sibai, MBBS, Maria Zigas, Arjun Datt Law, MBBS, MD DM, Umberto Falcone, MD, Solaf Sami Kanfar, MD, Naoko Sakurai, Vikas Gupta, MD PhD, Andre Schuh, MD FRCPC, Karen W.L. Yee, MD, Aaron Schimmer, MD PhD, Mark D. Minden, MD PhD, Dawn Maze, MD FRCPC, MSc, Steven M. Chan, MDPhD, Jack Seki, PharmD

Blood (2017) 130 (Supplement 1): 1283.

https://doi.org/10.1182/blood.V130.Suppl_1.1283.1283

Published: 2017

Journal Articles

Mutations In UBA3 Confer Resistance To The NEDD8-Activating Enzyme Inhibitor MLN4924 In Human Leukemic Cells

G. Wei Xu, MD, PhD, Julia I. Toth, PhD, Sara R. da Silva, BSc, Stacey-Lynn Paiva, BSc, Julie L. Lukkarila, PhD, Rose Hurren, Neil Maclean, BSc, Mahadeo A. Sukhai, PhD, Rabindra N. Bhattacharjee, PhD, Carolyn A. Goard, PhD, Bruno C Medeiros, MD, Patrick T. Gunning, PhD, Sirano Dhe-Paganon, PhD, Matthew D. Petroski, PhD, Aaron Schimmer, PhD, MD

Blood (2013) 122 (21): 2527.

https://doi.org/10.1182/blood.V122.21.2527.2527

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma?

The mitochondrial protease YME1L regulates type 1 interferon signaling via the cgas-sting pathway in AML

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1/FLT3/DNMT3a triple-mutated AML

Comparable remission rates in therapy-related and myelodysplasia-related Acute Myeloid Leukemia (AML) versus de novo AML treated with azacitidine and venetoclax: A contemporary real-world study.

Extramedullary disease in AML: A high-risk feature beyond ELN 2022 classification

Morphologic leukemia-free state (MLFS) is associated with inferior outcomes in patients with Acute Myeloid Leukemia (AML) treated with front-line azacitidine plus venetoclax

Prognostic relevance of multiparameter flow cytometry-based MRD assessment in patients with FLT3-ITD mutated AML considering concomitant mutations including DNMT3A/NPM1/WT1 mutation

Ribosome biogenesis and its regulation by the exportin, CSE1L, are targetable vulnerabilities in childhood and young adult Acute Myeloid Leukemia

Real-world evidence evaluation of the safety and efficacy of intensive chemotherapy with or without gemtuzumab ozogamicin (GO) in patients with newly diagnosed Acute Myeloid Leukemia (AML) and favorable or intermediate risk cytogenetics

Mixed phenotype acute leukemia: Clinical characteristics and real-world outcomes

Prognostic impact of molecular genetic and cytogenetic alterations in newly diagnosed acute myeloid leukemia treated with azacitidine and venetoclax: A real-world cohort study

Real-World Experience with CPX-351 for Secondary Acute Myeloid Leukemia: Comparison with FLAG-IDA in a Propensity Score Matching Analysis

Analysis of Chip Mutations Pre-and Post-Transplant in Multiple Myeloma (MM): Expanded Results from a Prospective Longitudinal Study

Mitochondrial Dysfunction in Normal and Malignant Hematopoiesis

The Mitochondrial Protease, Neurolysin (NLN), Regulates Respiratory Chain Supercomplex Formation and Represents a New Therapeutic Target for AML

Targeting the Mitochondrial Metallochaperone Cox17 Reduces DNA Methylation and Promotes AML Differentiation through a Copper Dependent Mechanism

Tafazzin (TAZ) Regulates the Differentiation of AML Cells By Reducing Levels of the Phospholipid Phosphatidylethanolamine

The Utility of Early Broncholaveolar Lavage in Prolonged Neutropenic Patients with Pulmonary Nodules

Migration in the Management of Philadelphia Positive ALL: Towards a Lower Risk of VTE

Mutations In UBA3 Confer Resistance To The NEDD8-Activating Enzyme Inhibitor MLN4924 In Human Leukemic Cells

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only